Abhishek Chandrakant Sawant

Abhishek Chandrakant Sawant

Auto-generated profile, based on publicly available information

Abhishek Chandrakant Sawant

University of Arizona College of Medicine, Phoenix, Arizona

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
PDF file
JGJudith A. Groeneweg
Judith A. Groeneweg
ABAditya Bhonsale
Aditya Bhonsale
CJCynthia A. James
Cynthia A. James
ARAnneline S. Te Riele
Anneline S. Te Riele
DDDennis Dooijes
Dennis Dooijes
HCHugh Calkins
Hugh Calkins
Background—: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a progressive cardiomyopathy. We aimed to define long-term outcome in a transatlantic cohort of 1001 individuals. Methods and Results—: Clinical and genetic characteristics and follow-up data of ARVD/C index-patients (n=439, fulfilling of 2010 criteria in all) and family members (n=562) were assessed. Mutations were identified in 276 index-patients (63%). Index-patients presented predominantly with sustained ventricular arrhythmias (268; 61%). During a median follow-up of 7 years, 301 of the 416 index-patients presenting alive (72%) experienced sustained ventricular arrhythmias. Sudden cardiac death during follow-up occurred more frequently among index-patients without an implantable cardioverter-defibrillator (10/63, 16% versus 2/335, 0.6%). Overall, cardiac mortality and the need for cardiac transplantation were low (6% and 4%, respectively). Clinical characteristics and outcomes were similar in index-patients with and without mutations, as well as in those with familial and nonfamilial ARVD/C. ARVD/C was diagnosed in 207 family members (37%). Symptoms at first evaluation correlated with disease expression. Family members with mutations were more likely to meet Task Force Criteria for ARVD/C (40% versus 18%), experience sustained ventricular arrhythmias (11% versus 1%), and die from a cardiac cause (2% versus 0%) than family members without mutations. Conclusions—: Long-term outcome was favorable in diagnosed and treated ARVD/C index-patients and family members. Outcome in index-patients was modulated by implantable cardioverter-defibrillator implantation, but not by mutation status and familial background of disease. One third of family members developed ARVD/C. Outcome in family members was determined by symptoms at first evaluation and mutations.

17 December 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ASAbhishek C. Sawant
Abhishek C. Sawant
ABAditya Bhonsale
Aditya Bhonsale
ARAnneline S. J. M. Te Riele
Anneline S. J. M. Te Riele
CTCrystal Tichnell
Crystal Tichnell
BMBrittney Murray
Brittney Murray
CJCynthia A. James
Cynthia A. James
Background: Exercise is associated with age‐related penetrance and arrhythmic risk in carriers of arrhythmogenic right ventricular dysplasia/cardiomyopathy ( ARVD /C)‐associated desmosomal mutations; however, its role in patients without desmosomal mutations (gene‐elusive) is uncertain. This study investigates whether exercise is (1) associated with onset of gene‐elusive ARVD /C and (2) has a differential impact in desmosomal and gene‐elusive patients. Methods and Results: Eighty‐two ARVD /C patients (39 desmosomal, all probands) were interviewed about regular physical activity from age 10. Participation in endurance athletics, duration (hours/year), and intensity ( MET ‐Hours/year) of exercise prior to clinical presentation were compared between patients with desmosomal and gene‐elusive ARVD /C. All gene‐elusive patients were endurance athletes. Gene‐elusive patients were more likely to be endurance athletes ( P <0.001) and had done significantly more intense ( MET ‐Hrs/year) exercise prior to presentation ( P <0.001), particularly among cases presenting < age 25 ( P =0.027). Family history was less prevalent among gene‐elusive patients (9% versus 40% desmosomal, P <0.001), suggesting a greater environmental influence. Gene‐elusive patients without family history did considerably more intense exercise than other ARVD /C patients ( P =0.004). Gene‐elusive patients who had done the most intense (top quartile MET ‐Hrs/year) exercise prior to presentation had a younger age of presentation ( P =0.025), greater likelihood of meeting ARVD /C structural Task Force Criteria (100% versus 43%, P =0.02), and shorter survival free from a ventricular arrhythmia in follow‐up ( P =0.002). Conclusions: Gene‐elusive, non‐familial ARVD /C is associated with very high intensity exercise suggesting exercise has a disproportionate role in the pathogenesis of these cases. As exercise negatively modifies cardiac structure and promotes arrhythmias, exercise restriction is warranted.

1 January 2016 in Heart Rhythm
Verified
Journal Article
Closed access
ASAbhishek C. Sawant
Abhishek C. Sawant
ARAnneline S.J.M. Te Riele
Anneline S.J.M. Te Riele
CTCrystal Tichnell
Crystal Tichnell
BMBrittney Murray
Brittney Murray
ABAditya Bhonsale
Aditya Bhonsale
CJCynthia A. James
Cynthia A. James

1 April 2015 in Heart Rhythm
Verified
Journal Article
Closed access
BPBinu Philips
Binu Philips
ARAnneline S.J.M. Te Riele
Anneline S.J.M. Te Riele
ASAbhishek Sawant
Abhishek Sawant
VKVishnupriya Kareddy
Vishnupriya Kareddy
CJCynthia A. James
Cynthia A. James
HTHarikrishna Tandri
Harikrishna Tandri

29 October 2014 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
ASAbhishek C. Sawant
Abhishek C. Sawant
PAPrabhat Adhikari
Prabhat Adhikari
SNSwapna R. Narra
Swapna R. Narra
SSSanjay Srivatsa
Sanjay Srivatsa
PMPaul K. Mills
Paul K. Mills
Background: Several inflammation biomarkers have been implicated in the pathogenesis and prognosis of acute coronary syndromes. However, the prognostic role of the neutrophil-lymphocyte white cell interactive response to myocardial injury in predicting short- and long-term mortality after ST elevation myocardial infarction (STEMI) remains poorly defined. Methods: We evaluated 250 consecutive STEMI patients presenting acutely for revascularization to our tertiary care center over 1 year. Patients with acute sepsis, trauma, recent surgery, autoimmune diseases, or underlying malignancy were excluded. Data gathered included demographics, clinical presentation, leukocyte markers, electrocardiograms, evaluations, therapy,major adverse cardiac events, and all-cause mortality. Results: Mean age was 62 ± 15 years, 70.4% of subjects were males while majority (49.4%) were Caucasians. Mean duration of follow-up was 571 ± 291 days (median 730 days). Univariate analysis of several inflammatory biomarkers including C-reactive protein, revealed white cell count (OR = 1.09, p < 0.001) and neutrophil to lymphocyte ratio (NLR) (OR = 1.05, p = 0.011) as predictors of short- and long-term mortality; but not mean neutrophil count (OR = 1.04, p = 0.055) or lymphocyte count alone (OR = 0.96, p = 0.551). Multivariate analysis using backward stepwise regression revealed NLR (OR = 2.64, p = 0.026), female gender (OR = 5.35, p < 0.001), cerebrovascular accident history (OR = 3.36, p = 0.023), low glomerular filtration rate (OR = 0.98, p = 0.012) and cardiac arrest on admission (OR = 17.43, p < 0.001) as robust independent predictors of long-term mortality. NLR was divided into two sub-groups based on an optimal cut off value of 7.4. This provided the best discriminatory cut off point for predicting adverse mortality outcome. Both short-term (≤ 30 days) and long-term (≤ 2 years) mortality were predicted with Kaplan-Meier survival curve separation best stratified by a NLR cut off value of 7.4. Conclusions: NLR based on an optimal cut off value of 7.4, was an excellent predictor of short- and long-term survival in patients with revascularized STEMI and warrants larger scale multi-center prospective evaluation, as a prognostic indicator. NLR offers improved prognostic capacity when combined with conventional clinical scoring systems, such as the Thrombolysis In Myocardial Infarction risk score. Background: Several inflammation biomarkers have been implicated in the pathogenesis and prognosis of acute coronary syndromes. However, the prognostic role of the neutrophil-lymphocyte white cell interactive response to myocardial injury in predicting short- and long-term mortality after ST elevation myocardial infarction (STEMI) remains poorly defined. Methods: We evaluated 250 consecutive STEMI patients presenting acutely for revascularization to our tertiary care center over 1 year. Patients with acute sepsis, trauma, recent surgery, autoimmune diseases, or underlying malignancy were excluded. Data gathered included demographics, clinical presentation, leukocyte markers, electrocardiograms, evaluations, therapy,major adverse cardiac events, and all-cause mortality. Results: Mean age was 62 ± 15 years, 70.4% of subjects were males while majority (49.4%) were Caucasians. Mean duration of follow-up was 571 ± 291 days (median 730 days). Univariate analysis of several inflammatory biomarkers including C-reactive protein, revealed white cell count (OR = 1.09, p < 0.001) and neutrophil to lymphocyte ratio (NLR) (OR = 1.05, p = 0.011) as predictors of short- and long-term mortality; but not mean neutrophil count (OR = 1.04, p = 0.055) or lymphocyte count alone (OR = 0.96, p = 0.551). Multivariate analysis using backward stepwise regression revealed NLR (OR = 2.64, p = 0.026), female gender (OR = 5.35, p < 0.001), cerebrovascular accident history (OR = 3.36, p = 0.023), low glomerular filtration rate (OR = 0.98, p = 0.012) and cardiac arrest on admission (OR = 17.43, p < 0.001) as robust independent predictors of long-term mortality. NLR was divided into two sub-groups based on an optimal cut off value of 7.4. This provided the best discriminatory cut off point for predicting adverse mortality outcome. Both short-term (≤ 30 days) and long-term (≤ 2 years) mortality were predicted with Kaplan-Meier survival curve separation best stratified by a NLR cut off value of 7.4. Conclusions: NLR based on an optimal cut off value of 7.4, was an excellent predictor of short- and long-term survival in patients with revascularized STEMI and warrants larger scale multi-center prospective evaluation, as a prognostic indicator. NLR offers improved prognostic capacity when combined with conventional clinical scoring systems, such as the Thrombolysis In Myocardial Infarction risk score.

27 August 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ARAnneline S.J.M. Te Riele
Anneline S.J.M. Te Riele
CJCynthia A. James
Cynthia A. James
JGJudith A. Groeneweg
Judith A. Groeneweg
ASAbhishek C. Sawant
Abhishek C. Sawant
KKKai Kammers
Kai Kammers
HTHarikrishna Tandri
Harikrishna Tandri
A combination of variable expression, age-related penetrance, and unpredictable arrhythmic events complicates management of relatives of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) patients. We aimed to (i) determine predictors of ARVD/C diagnosis and (ii) optimize arrhythmic risk stratification among first-degree relatives of ARVD/C patients. Detailed phenotypic and outcome data of 274 first-degree relatives (46% male; 36.5 ± 18.9 years) of 138 ARVD/C probands were obtained. Ninety-six (35%) relatives were diagnosed with ARVD/C according to 2010 Task Force Criteria (TFC). Siblings had a three-fold-increased risk of ARVD/C diagnosis compared with parents and children (odds ratio 3.11, P < 0.001). Multivariable logistic regression identified symptoms (P < 0.001), being a sibling (P < 0.001), the presence of a pathogenic mutation (P < 0.001), and female sex (P = 0.010) as predictors of ARVD/C diagnosis. During 6.7 ± 3.8 years of follow-up, 21 (8%) relatives experienced a sustained ventricular arrhythmia (cycle length 271 ± 48 ms). While being a sibling was a predictor of ARVD/C diagnosis, neither relatedness to the proband (P = 0.185) nor malignant family history (P = 0.347) was significantly associated with arrhythmic events. Meeting TFC independent of family history criteria had higher prognostic value for arrhythmic events than conventional 2010 TFC, which include family history [area under the receiver operating characteristic curve 0.95 (95% CI 0.93–0.97) vs. 0.85 (95% CI 0.82–0.88), P < 0.001]. One-third of first-degree relatives develop manifest ARVD/C. Siblings have highest risk of disease, even after correcting for age and sex. Fulfilment of TFC independent of family history is superior to conventional TFC for arrhythmic risk stratification of relatives.